David Butler - Concepedia

Author

David Butler

Alnylam Pharmaceuticals (United States)ORCID

Also Known As

D Butler, D. BUTLER, D. Butler, DAVID F. BUTLER, David Butler, David Christopher Butler, David F Butler, David F. Butler

119

Publications

5.6K

Citations

H-Index

108

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)Neural Stem Cell Institute University of Connecticut University of North Carolina at Pembroke Children's Mercy Hospital

About

David Butler is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	1.2K
2	Engineering	3	3	230
3	Natural Sciences	2	2	475
4	Health Sciences	1	1	20
5	Social Sciences	1	1	58

David Butler

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui, Angewandte Chemie International Edition	2012	1.2K
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson, Proceedings of the National Academy of Sciences	2008	635
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics Martin A. Maier, Muthusamy Jayaraman, Shigeo Matsuda, Molecular Therapy	2013	594
Analysis of Gunshot Residue and Associated Materials—A Review Oliver Dalby, David Butler, Jason Birkett Journal of Forensic Sciences	2010	400
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues: A Promising Class of Monoamine Uptake Inhibitors Peter C. Meltzer, David Butler, Jeffrey R. Deschamps, Journal of Medicinal Chemistry Monoamine Uptake InhibitorsPharmacotherapyLead CompoundPharmaceutical ChemistryMedicinal Chemistry	2006	399
Syringoma presenting as milia Stephen J. Friedman, David Butler Journal of the American Academy of Dermatology Surgical PathologyHistopathologyDiagnosisPathologyLymphatic Filariasis	1987	157
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui, Angewandte Chemie NanoparticlesFvii Ed50Lipid AnalysisEngineeringGene Delivery	2012	152
A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies Celeste M. Karch, Aimee W. Kao, Anna Karydas, Stem Cell Reports	2019	105
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model Diptaman Chatterjee, Mansi A. Bhatt, David Butler, npj Parkinson s Disease	2018	97
Protective Effects of Positive Lysosomal Modulation in Alzheimer's Disease Transgenic Mouse Models David Butler, Jeannie Hwang, Candice Estick, PLoS ONE	2011	93

Page 1